By Annisa Sofia 
The intricate dance between Alzheimer’s disease and the brain’s immune system has taken a significant step forward with groundbreaking research from the VIB and KU Leuven Center for Brain & Disease Research. Scientists have pinpointed the precise mechanism by which lecanemab, a monoclonal antibody treatment marketed as Leqembi, effectively targets and clears the toxic amyloid plaques characteristic of Alzheimer’s, while simultaneously slowing cognitive decline. This seminal study, published in the prestigious journal Nature Neuroscience, reveals that a specific component of the antibody, the ‘Fc fragment’, acts as a critical trigger for microglia, the brain’s resident immune cells, prompting them to initiate the removal of these damaging protein deposits.
For years, the precise modus operandi of anti-amyloid antibody therapies like lecanemab remained a subject of scientific inquiry, despite the treatment’s demonstrated clinical benefits. This new research provides the first comprehensive explanation, resolving long-standing questions and paving the way for the development of even safer and more potent Alzheimer’s therapies.
The Crucial Role of the Fc Fragment in Microglial Activation
Dr. Giulia Albertini, co-first author of the study, emphasized the study’s significance: "Our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer’s disease. We show that the therapy’s efficacy relies on the antibody’s Fc fragment, which activates microglia to effectively clear amyloid plaques." She elaborated on the mechanism, explaining, "The Fc fragment works as an anchor that microglia latch onto when they are near plaques, as a consequence of which these cells are reprogrammed to clear plaques more efficiently."
This discovery is particularly important because, while microglia are known to surround amyloid plaques in the Alzheimer’s brain, their ability to clear these toxic aggregates independently is often insufficient. Lecanemab, by leveraging the Fc fragment, essentially provides a directive to these immune cells, enhancing their natural, albeit impaired, plaque-clearing capabilities.
Alzheimer’s Disease: A Growing Global Challenge and the Microglial Defense
Alzheimer’s disease, a devastating neurodegenerative disorder, currently affects over 55 million people worldwide, a number projected to escalate significantly in the coming decades due to aging global populations. The hallmark pathology of the disease is the progressive accumulation of amyloid-beta plaques in the brain. These abnormal protein clusters are believed to initiate a cascade of events leading to neuronal dysfunction, synapse loss, and ultimately, the profound cognitive impairment and dementia that characterize the disease.
The brain’s innate immune system, primarily comprised of microglia, plays a dual role in Alzheimer’s. While microglia are drawn to the vicinity of amyloid plaques and attempt to engulf and clear them, their efficiency is often compromised in the disease state. This impaired clearance contributes to the relentless buildup of plaques and subsequent neurodegeneration. Therapeutic strategies, therefore, have increasingly focused on restoring or augmenting this crucial immune function.
Lecanemab: A Promising Antibody Therapy Under Scrutiny
Lecanemab, a humanized monoclonal antibody, represents a significant advancement in this therapeutic arena. It is designed to bind specifically to amyloid-beta aggregates, including protofibrils and mature plaques, facilitating their removal from the brain. In clinical trials, lecanemab has demonstrated a statistically significant slowing of cognitive decline in individuals with early-stage Alzheimer’s disease. The U.S. Food and Drug Administration (FDA) granted traditional approval for lecanemab (marketed as Leqembi) in July 2023, following an accelerated approval pathway.
Despite its clinical promise, the full therapeutic potential of lecanemab has been somewhat tempered by the occurrence of side effects, notably amyloid-related imaging abnormalities (ARIA), which can manifest as swelling or microhemorrhages in the brain. Understanding the precise mechanisms underlying lecanemab’s action is therefore paramount not only for optimizing its use but also for designing next-generation treatments that are both more effective and safer.
Deconstructing the Antibody: The Significance of the Fc Fragment
Antibodies are Y-shaped proteins with two primary functional regions. The ‘Fab’ (fragment antigen-binding) regions are responsible for recognizing and binding to specific targets, such as amyloid plaques in the case of lecanemab. The ‘Fc’ (fragment crystallizable) region, located at the base of the Y, interacts with other components of the immune system, including immune cells like microglia. It acts as a signaling platform, alerting these cells to the presence of a target that needs to be addressed.
While earlier research had hinted at the involvement of microglia in the plaque-clearing process mediated by antibodies, direct experimental proof linking the Fc fragment of lecanemab to this activity was previously elusive. Some scientific hypotheses even suggested that plaque removal might occur through Fc-independent mechanisms, adding a layer of complexity to the understanding of these therapies. The VIB-KU Leuven team, led by Professor Bart De Strooper, aimed to definitively settle this debate. Their meticulous research demonstrated unequivocally that the Fc fragment is not merely an accessory but an indispensable component for lecanemab’s efficacy. They observed that microglia only initiated a significant response and began clearing plaques when the Fc fragment of the antibody was intact and functional.
Advanced Experimental Models Uncover Human Microglial Responses
To rigorously investigate the interaction between lecanemab and human microglia, the researchers employed a sophisticated experimental approach. They utilized a specially engineered Alzheimer’s mouse model that had been engrafted with human microglial cells. This innovative model allowed for the direct observation of how lecanemab interacts with human immune cells within a controlled environment, providing a level of resolution and specificity previously unattainable.
"The fact that we used human microglia within a controlled experimental model was a major strength of our study," stated Magdalena Zielonka, co-first author. "This allowed us to test the very antibodies used in patients and observe human-specific responses with unprecedented resolution." The experimental setup proved critical: when the Fc fragment was experimentally removed from lecanemab, the antibody completely lost its ability to induce plaque clearance, underscoring its essential role.
Illuminating the Plaque-Clearing Cascade: Phagocytosis and Gene Expression
Having established the Fc fragment’s indispensable role, the researchers delved deeper into the cellular processes activated in microglia following Fc-mediated signaling. They meticulously examined how these activated microglia subsequently engage in the removal of amyloid plaques. The study identified key cellular mechanisms, including phagocytosis – the process by which cells engulf and internalize foreign particles – and lysosomal activity, where cellular waste is broken down. Crucially, these plaque-clearing processes were only observed to be triggered when the Fc fragment was present and functional. In the absence of an intact Fc fragment, the microglia remained largely quiescent and ineffective in clearing the amyloid deposits.
Further augmenting their findings, the research team employed cutting-edge techniques such as single-cell and spatial transcriptomics. These advanced methods allowed them to analyze the gene expression patterns within individual microglia. They identified a distinct gene activity signature in microglia associated with effective plaque removal. A key marker of this signature was the strong expression of the gene SPP1 (also known as Osteopontin). This specific gene expression profile was uncovered using NOVA-ST, a novel computational method developed within the Stein Aerts lab at VIB-KU Leuven, which is designed for high-resolution spatial transcriptomic analysis. The identification of this specific genetic program provides a molecular blueprint for successful microglial-mediated plaque clearance.
Implications for Future Alzheimer’s Therapeutics: Beyond Antibody Reliance
The profound insights gained from this research have significant implications for the future development of Alzheimer’s treatments. By precisely defining the microglial program responsible for clearing amyloid plaques, the findings open up new avenues for therapeutic intervention. The understanding that the Fc fragment acts as a bridge to activate microglia suggests that future therapies might be designed to directly stimulate these immune cells, potentially bypassing the need for antibodies altogether.
Professor Bart De Strooper concluded, "This opens doors to future therapies that may activate microglia without requiring antibodies. Understanding the importance of the Fc fragment helps guide the design of next-generation Alzheimer’s drugs." This could lead to treatments that are not only more targeted and potent but also potentially safer, by avoiding some of the side effects associated with antibody-based therapies, such as ARIA.
The research underscores the potential of developing small molecules or other biological agents that can mimic the signaling function of the Fc fragment, thereby directly engaging and reprogramming microglia for enhanced plaque clearance. Such an approach could offer a paradigm shift in how Alzheimer’s disease is treated, moving beyond plaque removal alone to actively harnessing the brain’s own immune defenses.
A Collaborative Effort Fueled by Global Support
This groundbreaking research was conducted at the VIB-KU Leuven Center for Brain & Disease Research, a leading institution at the forefront of neuroscience research. The study received vital financial support from a consortium of esteemed organizations, reflecting the global commitment to combating Alzheimer’s disease. These include the European Research Council (ERC), the Alzheimer’s Association USA, the Research Foundation Flanders (FWO), the Queen Elisabeth Medical Foundation for Neurosciences, Stichting Alzheimer Onderzoek — Fondation Recherche Alzheimer (STOPALZHEIMER.BE), KU Leuven, VIB, and the UK Dementia Research Institute at University College London. This collaborative funding landscape highlights the international urgency and scientific consensus surrounding the need for accelerated progress in Alzheimer’s research.
The implications of this study extend beyond the immediate clinical application of lecanemab. By providing a clear molecular understanding of how an effective Alzheimer’s therapy engages the brain’s immune system, the VIB-KU Leuven researchers have laid a robust foundation for the next wave of therapeutic innovation. The journey towards a cure for Alzheimer’s disease is complex and multifaceted, but this research marks a significant milestone, illuminating a critical pathway and offering renewed hope for millions affected by this relentless condition. The detailed exposition of the Fc fragment’s role is not just an academic triumph; it is a critical piece of the puzzle that will guide the development of more refined, effective, and potentially safer interventions for Alzheimer’s disease in the years to come.